digital-pathology-2016_scientifictracks-abstracts

Notes:

Page 37

Digital Pathology & Pathologists 2016

December 05-06, 2016

Volume 6 Issue 5(Suppl)

J Clin Exp Pathol

ISSN: 2161-0681 JCEP, an open access journal

conferenceseries

.com

December 05-06, 2016 Madrid, Spain

World Digital Pathology & Pathologists Congress

Eman Kandeel, J Clin Exp Pathol 2016, 6:5(Suppl)

Estimation of stem cell frequency in acute myeloid leukemia at diagnosis: Relation to hematological

and clinical parameters

Eman Kandeel

Cairo University, Egypt

Background:

Acute myeloid leukemia (AML) outcome is inferior to acute lymphoblastic leukemia. Treatment failure is largely

attributed to the persistence of leukemia stem cells (LSCs) which are less accessible and hence less responsive to chemo-

therapeutics.

Aim:

To demonstrate the impact of LSCs frequency at diagnosis and at follow up periods as compared to minimal residual

disease (MRD) on overall survival (OS) and disease free survival (DFS).

Methods:

The study was performed on 84 adult AML patients. Panels used CD38FITC/CD123PE/CD34ECD/CD45PE-PC5

and CD90FITC/CD133PE/CD45ECD/CD33PE-PC5 analyzed on Navios Flow cytometer. Cell populations with different

surface markers were calculated using the prism function of the software. The study was performed according to Helsinki

declaration for studies on human subjects and approved by the Institution Review Board (IRB) of the National Cancer Institute,

Cairo University. An informed signed consent was obtained from all study subjects before enrollment.

Results:

A higher CD 123% at diagnosis (p≤0.001) and at day (d) 14 (p=0.004 & p≤0.001 respectively) had an adverse impact

on OS and DFS. A higher CD 133% at diagnosis and at d14 (P=0.006 & P≤0.001 and P≤0.001 & P≤0.001 respectively), had

an adverse impact on OS and DFS. A higher [CD34-/CD38+/CD123+] percentage at diagnosis (P=0.025 and P≤0.001) had

adverse impact on OS and DFS at d14 (P=0.029) had adverse impact only on DFS.

Conclusion:

High frequency of LSCs reflects a higher percentage of chemotherapy resistant cells that will lead to the outgrowth

of MRD, thereby affecting clinical outcome.

Biography

Eman Kandeel has completed her MD in 2011 from NCI, Cairo University, Egypt. She has experience of Flow Cytometry from Roswell Park Cancer Institute,

Buffalo, New York. She is a Lecturer at BMT lab Clinical Pathology Department from 2011 to till date.